Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University.
Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 5 Similar Profiles
Renal Cell Carcinoma
Medicine & Life Sciences
Prostatic Neoplasms
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
Castration
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
docetaxel
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2013 2023
MISC_UniCanberra: Research into and Testing of Epigenetic based Biomarkers and companion therapeutics.
Gurney, H. & Cunningham, J.
1/04/19 → 30/04/20
Project: Other › Sponsored clinical trial
MISC_UniCanberra: Research into and Testing of Epigenetic based Biomarkers and companion therapeutics.
Gurney, H. & Cunningham, J.
1/04/19 → 30/04/20
Project: Other › Sponsored clinical trial
Misc_Novotech: A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study Comparing CB‐839 in Combination with Cabozantinib (CB‐Cabo) vs. Placebo with Cabozantinib (Pbo‐Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Gurney, H. & Cunningham, J.
17/07/18 → 5/06/23
Project: Other › Sponsored clinical trial
MISC_Covance Chiltern: A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients with Advanced Solid Tumors
Gurney, H., Butala, R. & Cunningham, J.
16/07/18 → 15/07/23
Project: Other › Sponsored clinical trial
A phase II randomised controlled trial of high dose Vitamin D in localised prostate cancer cases with intermediate risk of progression (Pros-D).
Gurney, H., Butala, R., Nair-Shalliker, V., Smith, D., Gebski, V., Patel, M., Frydenberg, M., Gardiner, R., Kimlin, M., Fenech, M. & Gillatt, D.
1/03/16 → …
Project: Research
Research Output 1987 2018
Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment
Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. & on behalf of PLATO collaborators, 1 Sep 2018, In : Journal of Clinical Oncology. 36, 25, p. 2639-2646 8 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Castration
Prostate-Specific Antigen
Prostatic Neoplasms
Prednisone
Control Groups
Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews
Van Leeuwen, M. T., Luu, S., Gurney, H., Brown, M. R., Webber, K., Pearson, S-A., Hunt, L. & Vajdic, C. M., 1 Jun 2018, In : BMJ Open. 8, 6, p. 1-6 6 p., e021064.Research output: Contribution to journal › Review article › Research › peer-review
Open Access
File
Ethics
Embolism and Thrombosis
Cerebrovascular Disorders
Neoplasms
Peer Review
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Gao, B., Lu, Y., Nieuweboer, A. J. M., Xu, H., Beesley, J., Boere, I., De Graan, A. J. M., De Bruijn, P., Gurney, H., Kennedy, C. J., Chiew, Y. E., Johnatty, S. E., Beale, P., Harrison, M., Luccarini, C., Conroy, D., Mathijssen, R. H. J., Harnett, P. R., Balleine, R. L., Chenevix-Trench, G. & 2 others, 1 Dec 2018, In : Scientific Reports. 8, 1, p. 1-10 10 p., 1508.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Genome-Wide Association Study
Carboplatin
Paclitaxel
Single Nucleotide Polymorphism
Drug Therapy
Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer
Vaughn, D. J., Bellmunt, J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Li, H., Perini, R. F., Bajorin, D. F. & de Wit, R., 1 Jun 2018, In : Journal of Clinical Oncology. 36, 16, p. 1579-1587 9 p.Research output: Contribution to journal › Article › Research › peer-review
Quality of Life
Drug Therapy
Neoplasms
Health Status
Research Personnel
Nivolumab in the treatment of advanced renal cell carcinoma
Arasaratnam, M. & Gurney, H., Jul 2018, In : Future Oncology. 14, 17, p. 1679-1689 11 p., 29460635.Research output: Contribution to journal › Article › Research › peer-review
Renal Cell Carcinoma
Neoplasms
Interleukin-2
Therapeutics
Biomarkers